March 11 (Reuters) - Europe's drugs regulator backed the use
of AstraZeneca's COVID-19 vaccine on Thursday, saying
its benefits outweighed the risks, after Denmark paused its use
following reports of blood clot formation in some who had been
vaccinated.
The European Medicines Agency (EMA), which called the
suspension a precautionary measure, said there was no indication
at present that vaccination had caused those conditions and the
vaccine can continue to be administered while its safety
committee investigates the cases of blood clot formations.
(Reporting by Muvija M in Bengaluru;Editing by Elaine
Hardcastle)
Astrazeneca (AZN)
